SCHEMBL17815212

SCHEMBL17815212

Cc1ccc(N)c2c1CN(C)CC2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.39
MAOA P21397 2/20 0.38
MAOB P27338 2/20 0.38
KDM4E B2RXH2 3/20 0.36
CYP2D6 P10635 3/20 0.36
CYP1A2 P05177 2/20 0.36
CHRNA7 P36544 1/20 0.36
ADRA1A P35348 4/20 0.36
ADRA2C P18825 3/20 0.36
ADRA2A P08913 3/20 0.36
ADRA2B P18089 2/20 0.36
ADRA1D P25100 2/20 0.36
ADRA1B P35368 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
DRD1 P21728 2/20 0.34
DRD3 P35462 2/20 0.34
DRD2 P14416 1/20 0.34
DRD4 P21917 1/20 0.34
DRD5 P21918 1/20 0.34
ALDH1A1 P00352 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8184550 0.80 CYP2C19 (0.38) CYP2C19MAOAMAOBKDM4ECYP2D6
SCHEMBL19705567 0.80 CYP2C19 (0.38) CYP2C19MAOAMAOBKDM4ECYP2D6
SCHEMBL13184293 0.78 ADRA2A (0.53) CYP2D6ADRA1AADRA2CADRA2AADRA2B
SCHEMBL17815299 0.78 MAOA (0.49) MAOAMAOBKDM4EDRD1DRD3
SCHEMBL8232020 0.78 CYP2C19 (0.39) CYP2C19MAOAMAOBKDM4ECYP2D6
SCHEMBL17197369 0.77 DRD1 (0.45) MAOAMAOBDRD1DRD3DRD2
SCHEMBL3023510 0.76 ADRA2A (0.44) CYP2C19MAOAMAOBKDM4ECYP2D6
SCHEMBL17815390 0.76 ALDH1A1 (0.44) MAOAMAOBKDM4ECYP2D6CYP1A2
SCHEMBL17815392 0.75 DRD1 (0.46) MAOAMAOBDRD1DRD3DRD2
SCHEMBL6608260 0.75 KDM4E (0.43) MAOAMAOBKDM4ECYP2D6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160158377-A1 BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same ABBVIE INC. (US) 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160158377-A1 BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same BCL2, BCL2L10, BAX CYP2C19 4571/4885MAOA 3022/4885MAOB 2603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.